N-(5-甲氧基-2-甲基-4-硝基苯基)乙酰胺 | 361162-90-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(5-甲氧基-2-甲基-4-硝基苯基)乙酰胺
• 中文别名: 2-乙酰氨基-4-甲氧基-5-硝基甲苯
• 英文名称: 5-methoxy-2-methyl-4-nitroacetanilide
• 英文别名: acetic acid-(5-methoxy-2-methyl-4-nitro-anilide)；Essigsaeure-(5-methoxy-2-methyl-4-nitro-anilid)；5-Nitro-2-acetamino-4-methoxy-toluol；N-(5-methoxy-2-methyl-4-nitro-phenyl)-acetamide；N-(5-methoxy-2-methyl-4-nitrophenyl)acetamide；2-Acetamido-4-methoxy-5-nitrotoluene
• CAS: 361162-90-5
• 化学式: C₁₀H₁₂N₂O₄
• mdl: MFCD12198895
• 分子量: 224.216
• InChiKey: UNGJDCICXXTFHD-UHFFFAOYSA-N

物化性质

• 熔点：
  139 °C
• 沸点：
  432.4±45.0 °C(Predicted)
• 密度：
  1.283±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  84.2
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  N-(5-甲氧基-2-甲基-4-硝基苯基)乙酰胺 在 potassium permanganate 、 diphenyl ether-biphenyl eutectic 、 硫酸 、 铁粉 、 magnesium sulfate 、 potassium carbonate 、 氯化铵 、 N,N-二异丙基乙胺 、 lithium chloride 、 三氯氧磷 作用下， 以 四氢呋喃 、 甲醇 、 水 、 N,N-二甲基甲酰胺 、 异丙醇 、 甲苯 为溶剂， 反应 46.75h， 生成 培利替尼
  参考文献：
  名称：

  Synthesis and Structure−Activity Relationships of 6,7-Disubstituted 4-Anilinoquinoline-3-carbonitriles. The Design of an Orally Active, Irreversible Inhibitor of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor (EGFR) and the Human Epidermal Growth Factor Receptor-2 (HER-2)

  摘要：

  A series of of 6,7-disubstituted-4-anilinoquinoline-3-carbonitrile derivatives that function as irreversible inhibitors of EGFR and HER-2 kinases have been prepared. These inhibitors have, at the 6-position, butynamide, crotonamide, and methacrylamide Michael acceptors bearing water-solublilizing substituents. These compounds were prepared by acylation of 6-amino-4-(arylamino)quinoline-3-carbonitriles with unsaturated acid chlorides or mixed anhydrides. We performed competitive reactivity studies showing that attaching a dialkylamino group onto the end of the Michael acceptor results in compounds with greater reactivity due to intramolecular catalysis of the Michael addition. This, along with improved water-solubility results in compounds with enhanced biological properties. We present molecular modeling results consistent with the proposed mechanism of inhibition. One compound, 5 (EKB-569), which shows excellent oral in vivo activity, was selected for further studies and is currently in phase I clinical trials for the treatment of cancer.

  DOI：

  10.1021/jm020241c
• 作为产物：
  描述：

  2-甲基-4-硝基-5-甲氧基苯胺 生成 N-(5-甲氧基-2-甲基-4-硝基苯基)乙酰胺
  参考文献：
  名称：

  Dadswell; Kenner, Journal of the Chemical Society, 1927, p. 586

  摘要：

  DOI：

文献信息

• PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
  申请人：Arora Nidhi

  公开号：US20120015962A1

  公开（公告）日：2012-01-19

  Compounds of the formula I or II: wherein X, m, Ar, R 1 and R 2 are as defined herein. The subject compounds are useful for treatment of IRAK-mediated conditions.

  式I或II的化合物： 其中X，m，Ar，R1和R2如本文所定义。所述化合物对于治疗IRAK介导的疾病是有用的。
• Method of treating or inhibiting colonic polyps
  申请人：American Cyanamid Company

  公开号：US06384051B1

  公开（公告）日：2002-05-07

  This invention provides a method of treating or inhibiting colonic polyps which comprises providing a compound of formula 1 wherein: R1, R2, R3, R4, X, Y, and n are as defined hereinbefore, or a pharmaceutically acceptable salt thereof.

  本发明提供了一种治疗或抑制结肠息肉的方法，包括提供如下公式1的化合物： 其中： R1、R2、R3、R4、X、Y和n如前文所定义，或其药用可接受的盐。
• Stabilized pharmaceutical composition containing basic excipients
  申请人：Wyeth Holdings Corporation

  公开号：US20040122048A1

  公开（公告）日：2004-06-24

  This invention provides a stable stabilized pharmaceutical composition in an oral dosage form comprising a compound of the formula 1 wherein: R 11 , R 10 , R 5 , R 6 , R 7 , R 8 , R, Y, X, k, p and n are as defined herein, or its pharmaceutically acceptable salts, esters or ethers thereof.

  本发明提供了一种稳定的口服剂型的药物组合物，包括式1的化合物，其中：R11、R10、R5、R6、R7、R8、R、Y、X、k、p和n如本文所定义，或其药学上可接受的盐、酯或醚。
• Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators
  申请人：Hoffmann-La Roche Inc.

  公开号：US09255110B2

  公开（公告）日：2016-02-09

  Compounds of the formula I or II: wherein X, m, Ar, R1 and R2 are as defined herein. The subject compounds are useful for treatment of IRAK-mediated conditions.

  式I或II的化合物： 其中X，m，Ar，R1和R2的定义如本文所述。该化合物对于治疗IRAK介导的疾病是有用的。
• PYRAZOLO[1,5A]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP3252054A1

  公开（公告）日：2017-12-06

  Compounds of the formula I or II: wherein X, m, Ar, R1 and R2 are as defined herein. The subject compounds are useful for treatment of IRAK-mediated conditions.

  式 I 或 II 的化合物： 其中 X、m、Ar、R1 和 R2 如本文所定义。上述化合物可用于治疗 IRAK 介导的病症。